Results 191 to 200 of about 45,803 (309)

Glucagon receptor (GCGR) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Glucagon-like peptide-1 agonists usage to widen the living donor pool for liver transplantation: A novel metabolic strategy. [PDF]

World J Transplant
Alnagar A, Khan MU, Ahmad MS, Mersal M, Ayyad M, Hassan R, Noormohamed MS.   +6 more
europepmc   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025

Obesity, EarlyView.
ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard, Jacob Harbo Andersen, Rebecca Kofod Vinding, Julie Tonsgaard Kloppenborg, Anton Pottegård   +4 more
wiley   +1 more source

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. [PDF]

Front Endocrinol (Lausanne)
Alhazmi A, le Roux CW.
europepmc   +1 more source

Glucagon Receptor Binding [PDF]

, 2020
openaire   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Contractile Effects of Glucagon in Mouse Cardiac Preparations. [PDF]

Int J Mol Sci
Neumann J, Schmidt F, Braekow P, Kirchhefer U, Klimas J, Hadova K, Gergs U.   +6 more
europepmc   +1 more source

Appetite Suppression by GLP‐1 Receptor Agonists: Role of Delayed Gastric Emptying

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate relationships between delayed gastric emptying and appetite suppression during treatment with liraglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA). Methods We conducted a secondary data analysis from a 16‐week randomized, placebo‐controlled liraglutide trial in patients with obesity.
Mark I. Friedman, W. Scott Harmsen, Michael Camilleri   +2 more
wiley   +1 more source

The gut-brain axis in avian appetite regulation: Integrating peripheral signals with central neurocircuitry. [PDF]

Poult Sci
Mahdavi K, Zendehdel M, Ghashghaei E, Lin H.   +3 more
europepmc   +1 more source